CYNK-201

N/A

Report date: 2023/12/04 16:38:53

Base Information

Drug NameCYNK-201
Drug Alias NameCD34-derived natural killer cells therapy(Celularity Inc)CYNK-201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsAnti-Low affinity immunoglobulin gamma Fc region receptor III-A
TargetsLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCelularity Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelularity Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A